On October 27, 2022 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that it will report third quarter 2022 financial results before U.S. financial markets open on Thursday, November 3, 2022 (Press release, Kura Oncology, OCT 27, 2022, View Source [SID1234622501]). Kura’s management will host a webcast and conference call at 8:00 a.m. ET / 5:00 a.m. PT that day to discuss the financial results and provide a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the teleconference, domestic callers should dial 1-888-394-8218 and international callers should dial 1-323-994-2093 and reference conference ID: 2251807. A live webcast presentation can also be accessed using this weblink: View Source;tp_key=fe0ec98bea. A replay of the webcast will be available online from the investor relations section of the company website at www.kuraoncology.com.